protocolSection identificationModule nctId: NCT06386315, orgStudyIdInfo id: MC230808, secondaryIdInfos id: NCI-2024-03242, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: 23-010273, type: OTHER, domain: Mayo Clinic Institutional Review Board, secondaryIdInfos id: MC230808, type: OTHER, domain: Mayo Clinic, briefTitle: Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-05-30, completionDateStruct date: 2024-05-30, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, descriptionModule briefSummary: This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patients with indolent non-Hodgkin lymphoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Standard of care radiation treatment for indolent non-Hodgkin lymphoma is usually delivered in 12 treatments. Studies have shown indolent lymphoma to be sensitive to radiation treatment, however, larger doses have higher rates of toxicities. A reduced radiation dose may be safe, tolerable and/or effective compared to standard of care radiation dose in treating patients with indolent non-Hodgkin lymphoma., conditionsModule conditions: Indolent B-Cell Non-Hodgkin Lymphoma, conditions: Recurrent Indolent B-Cell Non-Hodgkin Lymphoma, conditions: Refractory Indolent B-Cell Non-Hodgkin Lymphoma, conditions: Recurrent Indolent Non-Hodgkin Lymphoma, conditions: Refractory Indolent Non-Hodgkin Lymphoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 112, type: ESTIMATED, armsInterventionsModule interventions name: Computed Tomography, interventions name: Endoscopic Procedure, interventions name: Involved-site Radiation Therapy (3 Fractions), interventions name: Involved-site Radiation Therapy (12 Fractions), interventions name: Positron Emission Tomography, interventions name: Questionnaire Administration, outcomesModule primaryOutcomes measure: Incidence of grade 2 or higher acute adverse events (AEs), secondaryOutcomes measure: Response rate, secondaryOutcomes measure: Time to progression rate, secondaryOutcomes measure: Patient reported quality of life, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic in Arizona, city: Scottsdale, state: Arizona, zip: 85259, country: United States, contacts name: Clinical Trials Referral Office, role: CONTACT, phone: 855-776-0015, email: mayocliniccancerstudies@mayo.edu, contacts name: William G. Rule, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 33.50921, lon: -111.89903, locations facility: Mayo Clinic in Florida, city: Jacksonville, state: Florida, zip: 32224-9980, country: United States, contacts name: Clinical Trials Referral Office, role: CONTACT, phone: 855-776-0015, email: mayocliniccancerstudies@mayo.edu, contacts name: Bradford S. Hoppe, MD, MPH, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 30.33218, lon: -81.65565, locations facility: Mayo Clinic in Rochester, city: Rochester, state: Minnesota, zip: 55905, country: United States, contacts name: Clinical Trials Referral Office, role: CONTACT, phone: 855-776-0015, email: mayocliniccancerstudies@mayo.edu, contacts name: Scott C. Lester, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False